Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block may reduce Post-Surgery pain in breast cancer patients

NCT ID NCT04327063

Symptom relief Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a nerve block using ropivacaine could reduce pain after breast cancer surgery compared to a placebo. 182 women having breast-conserving surgery with sentinel lymph node biopsy took part. The goal was to see if fewer patients needed strong painkillers in the first three hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ropivacaine
What this could lead to
If it works, this could offer a better way to manage pain after breast cancer surgery, reducing the need for strong painkillers.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients or surgeries. The nerve block may not provide significant benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

182 people

The number who actually took part.

Started

Aug 2020

Finished

Jan 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women with non-metastatic invasive breast carcinoma or breast carcinoma in situ treated by breast-conserving surgery (tumorectomy) with sentinel node technique on one day surgery. 2. Age between 18 and 85 years. 3. ASA class 1, 2 or 3 4. Signed informed consent form. Exclusion Criteria: 1. Ongoing neoplasm or history of neoplasm other than breast cancer with the exception of: basal cell carcinoma, cervical carcinoma in situ, other treated cancer that has not relapsed during the 5 years preceding inclusion in the trial. 2. Axillary dissection planned during surgery planning 3. All bilateral surgery the day of Pecs administration 4. Metastatic breast carcinoma at diagnosis (M1). 5. Allergy to local anesthetics and morphine. 6. Use of analgesics during the 12 hours preceding the surgical procedure. 7. History of ipsilateral surgery during the previous 6 months. 8. History of substance abuse. 9. Pregnant woman or breastfeeding. 10. Subjects deprived of their liberty or under guardianship (including temporary guardianship). 11. Subjects no covered by social security scheme 12. Experiencing any psychiatric condition or major cognitive impairment that may hamper completion of self-reported questionnaires. There is no prohibition for people to take part simultaneously in another search and there is no exclusion cause at the end of the research period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast carcinoma in situ are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma in situ breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant neoplasm of breast

Contacts and locations

Locations

  • Centre Jean Perrin

    Clermont-Ferrand, 63000, France

  • Hopital Tenon

    Paris, 75020, France

  • Institut Curie

    Paris, 75005, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.